Avalglucosidase Alfa: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France), NICE (England) and PHARMAC (New Zealand), among others, recommended or restricted avalglucosidase alfa, while AOTMIT (Poland), DMC (Denmark) and PBAC (Australia) did not recommend it.
The record spans 3.3 years, opening at PBAC (Australia) in 2021 and running to 6 Nov 2024.
CIPM (Spain) changed its position: not recommended on 23 Oct 2023, recommended by 29 Jan 2024, after a resubmission.
No assessment is on file from TLV (Sweden) and G-BA (Germany), each among the eight highest-volume agencies here.
The file is active: 8 of 13 records date from 2023 or later.
3 distinct indication wordings are recorded for avalglucosidase alfa by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 13 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess avalglucosidase alfa, in 2021; PHARMAC (New Zealand) did not open a file until 6 Nov 2024 — a wide spread of 3.3 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 4 years in total.
2 of the 10 agencies here assessed avalglucosidase alfa more than once, CIPM (Spain) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
10 of the 18 agencies in this archive hold a record for avalglucosidase alfa.
The full ledger for avalglucosidase alfa reads 7 recommended, 5 not recommended and 1 deferred to NICE.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PHARMAC (New Zealand) | 6 Nov 2024 | Pompe disease, late onset (LOPD) | PTAC advice: Medium | source |
| ZIN (Netherlands) | 30 May 2024 | Advies - vergoed avalglucosidase alfa (Nexviadyme®) voor de behandeling van de ziekte van Pompe | reimbursed (sluis) | source |
| CIPM (Spain) | 13 Dec 2023 | Indicación terapéutica autorizada : Nexviadyme (avalglucosidasa alfa) está indicado como terapia enzimática de sustituci… | not financed by the SNS (financed 2024-01) | source |
| SMC (Scotland) | 10 Jul 2023 | Long-term enzyme replacement therapy (ERT) for the treatment of patients with Pompe disease (acid α-glucosidase (GAA) deficiency). | accepted | source |
| AOTMIT (Poland) | 5 Jul 2023 | Nexviadyme reimbursement recommendation | not recommended | source |
8 further decisions for avalglucosidase alfa, across 7 agencies, are not shown here. They link to 8 further source documents.
Related molecules
- teriparatide — also decided by PHARMAC in 2024Q4
- dexamethasone — also decided by PHARMAC in 2024Q4
- lanadelumab — also decided by PHARMAC in 2024Q4
- eliglustat — also decided by PHARMAC in 2024Q4
- cetuximab — also decided by PHARMAC in 2024Q4
- loncastuximab tesirine — also decided by ZIN in 2024Q2
Coverage: 13 decisions for avalglucosidase alfa from 10 agencies, 2021 to 2024. Data to 7 Sep 2026. ATC class A16 — Other alimentary tract and metabolism. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.